Twenty One Capital Inc (CEP) Stock News

A lawsuit was filed on July 24, 2026, against PROCEPT BioRobotics Corporation alleging the company misrepresented U.S. handpiece unit sales through an undisclosed discount program that incentivized bulk orders beyond actual demand, artificially inflating reported sales and exposing the company to material operational and financial risks.

Grabar Law Office announced investigations into potential breaches of fiduciary duties by officers and directors at Doximity, GoDaddy, Planet Fitness, and PROCEPT BioRobotics. The investigations follow federal securities class action filings alleging misleading statements regarding business metrics, pricing strategies, and financial guidance. Long-term shareholders meeting specific holding periods are eligible to seek corporate reforms and potential compensation at no cost.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about its business between February 2024 and February 2026. The company allegedly used an undisclosed discount program to artificially inflate handpiece sales, leading to excess inventory of over 10,000 units. Stock price declined significantly following three earnings announcements revealing lower-than-expected sales and inventory issues. Shareholders have until September 22, 2026 to file lead plaintiff motions.

Kaplan Fox has filed a class action lawsuit against PROCEPT BioRobotics Corporation for allegedly misleading investors about the relationship between handpiece unit sales and procedures. The complaint alleges that undisclosed discount programs artificially inflated reported U.S. handpiece unit sales and revenues by pulling forward demand. Investors who purchased PROCEPT common stock between February 28, 2024 and February 25, 2026 may be eligible to participate in the class action, with a deadline of September 22, 2026 to seek a lead plaintiff role.

A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly misleading investors about handpiece sales through undisclosed bulk discount programs that artificially inflated revenues. The company pulled forward sales from future quarters to meet expectations, resulting in excess customer inventory of over 10,000 units. PROCEPT shares declined over 48% from August 2025 to February 2026 as the truth emerged through a series of earnings misses and subsequent disclosures.

A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding handpiece unit sales and revenues. The lawsuit claims the company used undisclosed discount programs to artificially inflate sales figures, created excess inventory of over 10,000 units, and failed to disclose material risks. Investors who purchased stock between February 28, 2024 and February 25, 2026 may be eligible for compensation, with a September 22, 2026 deadline to serve as lead plaintiff.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding its handpiece unit sales and revenues. The company allegedly used an undisclosed extensive discount program to artificially inflate sales by pulling forward orders, creating over 10,000 excess units in field inventory and causing the company to miss its 2025 guidance. Investors who purchased stock between February 28, 2024 and February 25, 2026 can apply to be lead plaintiff by September 22, 2026.

Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) for violations of the Securities Exchange Act. The lawsuit alleges the company made false and misleading statements by using large discounts to inflate current revenue, pulling orders forward, and materially overstating handpiece unit utilization. The class period spans February 28, 2024 to February 25, 2026, with a September 22, 2026 deadline for investors to participate.

A securities class action has been filed against PROCEPT BioRobotics for allegedly misleading investors about handpiece sales performance. The company allegedly used undisclosed bulk order discount programs to artificially inflate sales figures by pulling forward future quarter sales, resulting in excess customer inventory exceeding 10,000 units. The stock declined over 48% from August 2025 to February 2026 as the truth emerged through quarterly earnings misses and management disclosures.

PROCEPT BioRobotics faces a securities fraud class action lawsuit for failing to disclose material inventory issues. The company revealed that handpiece sales had materially exceeded procedures since Q1 2023, resulting in over 10,000 units of excess field inventory. This disclosure caused the stock to decline 18% in two days, from $27.84 to $22.69 per share, as quarterly handpiece sales dropped nearly 30% and the company missed annual revenue guidance by tens of millions of dollars. Investors have until September 22, 2026 to file lead plaintiff applications.

Rosen Law Firm announces a September 22, 2026 deadline for investors to join a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges the company made materially false statements regarding its handpiece unit sales and revenues, claiming an undisclosed discount program artificially inflated sales figures, created excess inventory of over 10,000 units, and that the company could not achieve its 2025 guidance.

Rosen Law Firm is notifying investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) of a securities class action lawsuit with a September 22, 2026 lead plaintiff deadline. The lawsuit alleges that PROCEPT made materially false statements regarding its sales practices, including use of undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess inventory of over 10,000 units, and made unachievable 2025 guidance. Investors with losses exceeding $100,000 are encouraged to seek counsel.

Kirby McInerney LLP is reminding PROCEPT BioRobotics investors of the September 22, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges the company made false statements about handpiece unit sales by concealing an extensive discount program that artificially inflated revenues and created over 10,000 excess units in field inventory. Stock declined significantly following earnings misses and guidance reductions in August, November 2025, and February 2026.

PROCEPT BioRobotics Corporation faces a class action securities fraud lawsuit alleging the company used an undisclosed discount program to artificially inflate handpiece sales and revenues between February 2024 and February 2026. The scheme allegedly created excess field inventory of over 10,000 units and misled investors about business performance, resulting in significant stock price declines following quarterly earnings revelations.

Rosen Law Firm alerts PROCEPT BioRobotics investors with losses exceeding $100K about a September 22, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges PROCEPT made materially false statements regarding undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess field inventory exceeding 10,000 units, and rendered 2025 guidance unachievable.

Rosen Law Firm is notifying PROCEPT BioRobotics Corporation investors of a securities class action lawsuit with a September 22, 2026 lead plaintiff deadline. The lawsuit alleges that PROCEPT made materially false statements regarding its discount programs, handpiece unit sales, and revenue guidance. The company allegedly used undisclosed bulk order discounts that artificially inflated sales figures and created over 10,000 excess units of field inventory, exposing the company to material operational and financial risks.

A securities class action has been filed against PROCEPT BioRobotics for allegedly withholding information about handpiece sales practices. The company allegedly used undisclosed bulk order discount programs to artificially inflate sales by pulling forward orders from future quarters, resulting in excess customer inventory exceeding 10,000 units. The stock declined approximately 48% from August 2025 to February 2026 as the company made successive downward revisions and eventually disclosed the inventory issues.

Pomerantz Law Firm has filed a class action lawsuit against PROCEPT BioRobotics Corporation, alleging securities fraud and unlawful business practices. The lawsuit stems from the company's repeated mismanagement of inventory and missed sales guidance. PROCEPT failed to disclose that handpiece sales significantly exceeded procedures, resulting in over 10,000 units of excess field inventory. The company's stock declined sharply following three earnings announcements in 2025-2026, with the most recent showing a 30% sequential decline in quarterly handpiece sales. Investors have until September 22, 2026, to request Lead Plaintiff status.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false and misleading statements regarding its business operations. The company allegedly used undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess field inventory of over 10,000 units, and failed to disclose risks that prevented it from achieving 2025 guidance. Stock prices fell significantly following earnings announcements in August, November 2025, and February 2026 that revealed lower-than-expected sales and inventory management issues.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about its business between February 2024 and February 2026. The company allegedly used an undisclosed discount program to artificially inflate handpiece sales, creating excess inventory of over 10,000 units. Stock prices fell significantly following three earnings announcements revealing lower-than-expected sales and inventory issues. Shareholders have until September 22, 2026 to file lead plaintiff motions.

Rosen Law Firm reminds investors of the September 22, 2026 lead plaintiff deadline in a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its discount programs, handpiece unit sales, and revenue guidance. The company allegedly used undisclosed bulk order discounts that artificially inflated sales figures and created excess inventory of over 10,000 units, exposing the company to material operational and financial risks.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 to February 25, 2026). The complaint claims the company misrepresented that the differential between handpiece sales and procedures remained consistent, when in fact their sales tactics pulled forward demand artificially. The deadline to serve as lead plaintiff is September 22, 2026.

PROCEPT BioRobotics faces a securities class action lawsuit for failing to disclose material inventory issues. The company revealed on February 25, 2026 that handpiece sales had materially exceeded procedures since Q1 2023, resulting in over 10,000 units of excess field inventory. This disclosure caused the stock to plummet approximately 18% in two days, from $27.84 to $22.69 per share, as quarterly handpiece sales declined nearly 30% and the company missed annual revenue guidance by tens of millions of dollars. Investors who purchased shares between February 28, 2024 and February 25, 2026 have until September 22, 2026 to file lead plaintiff applications.

Pomerantz Law Firm has filed class action lawsuits against PROCEPT BioRobotics Corporation for alleged securities fraud. The lawsuit stems from PROCEPT's repeated missed sales guidance, accumulation of excess field inventory exceeding 10,000 units, and significant stock price declines following earnings announcements in August 2025, November 2025, and February 2026. Investors have until September 22, 2026, to join the class action.

A securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about product demand. The company allegedly used undisclosed discount programs to inflate handpiece unit sales, resulting in overstocking. PROCEPT's stock fell over 18% on February 25, 2026, when the company revealed that handpiece sales had consistently exceeded procedures. Investors have until September 22, 2026, to seek lead plaintiff status.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures. The company allegedly accumulated over 10,000 excess units in field inventory and was unable to achieve its 2025 guidance. The lead plaintiff deadline is September 22, 2026.

PROCEPT BioRobotics faces a securities class action lawsuit for allegedly failing to disclose material information about excess handpiece inventory and inflated sales figures during the Class Period (February 28, 2024 - February 25, 2026). The company is accused of misleading investors about U.S. handpiece sales that exceeded procedures, resulting in over 10,000 units of excess inventory that would cause significant revenue declines. Investors with losses exceeding $100,000 have until September 22, 2026 to file lead plaintiff applications.

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 - February 25, 2026). The firm is also pursuing cases against Hub Group, Inc. and investigating potential securities violations at Alignment Healthcare, Inc. Investors with losses are encouraged to contact the firm before respective deadlines.

Grabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging securities fraud. The company allegedly failed to disclose an extensive discount program that artificially inflated handpiece sales and revenues between February 2024 and February 2026. The undisclosed practices led to excess field inventory exceeding 10,000 units and significant stock price declines following quarterly earnings announcements. Shareholders who purchased PROCEPT securities during the class period have until September 22, 2026 to file a lead plaintiff motion.